These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 7692002)

  • 1. Phase I study of CPT-11 and etoposide in patients with refractory solid tumors.
    Karato A; Sasaki Y; Shinkai T; Eguchi K; Tamura T; Ohe Y; Oshita F; Nishio M; Kunikane H; Arioka H
    J Clin Oncol; 1993 Oct; 11(10):2030-5. PubMed ID: 7692002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer.
    Masuda N; Fukuoka M; Kudoh S; Matsui K; Kusunoki Y; Takada M; Nakagawa K; Hirashima T; Tsukada H; Yana T
    J Clin Oncol; 1994 Sep; 12(9):1833-41. PubMed ID: 7521905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I clinical trial of irinotecan (CPT-11), 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, and cisplatin in combination with fixed dose of vindesine in advanced non-small cell lung cancer.
    Shinkai T; Arioka H; Kunikane H; Eguchi K; Sasaki Y; Tamura T; Ohe Y; Oshita F; Nishio M; Karato A
    Cancer Res; 1994 May; 54(10):2636-42. PubMed ID: 8168091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.
    Abigerges D; Chabot GG; Armand JP; Hérait P; Gouyette A; Gandia D
    J Clin Oncol; 1995 Jan; 13(1):210-21. PubMed ID: 7799022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer.
    Masuda N; Fukuoka M; Kudoh S; Kusunoki Y; Matsui K; Nakagawa K; Hirashima T; Tamanoi M; Nitta T; Yana T
    J Clin Oncol; 1994 Jan; 12(1):90-6. PubMed ID: 7505810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer.
    Masuda N; Matsui K; Negoro S; Takifuji N; Takeda K; Yana T; Kobayashi M; Hirashima T; Kusunoki Y; Ushijima S; Kawase I; Tada T; Sawaguchi H; Fukuoka M
    J Clin Oncol; 1998 Oct; 16(10):3329-34. PubMed ID: 9779709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study of a weekly infusion of irinotecan hydrochloride (CPT-11) and a 14-day continuous infusion of etoposide in patients with lung cancer: JCOG trial 9408.
    Fujishiro M; Shinkai T; Fukuda M; Tamura T; Ohe Y; Kunitoh H; Nishiwaki Y; Sekine I; Fukuda H; Saijo N
    Jpn J Clin Oncol; 2000 Nov; 30(11):487-93. PubMed ID: 11155918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study.
    Miller AA; Hargis JB; Lilenbaum RC; Fields SZ; Rosner GL; Schilsky RL
    J Clin Oncol; 1994 Dec; 12(12):2743-50. PubMed ID: 7527456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 7-Ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy camptothecin: mechanism of resistance and clinical trials.
    Saijo N; Nishio K; Kubota N; Kanzawa F; Shinkai T; Karato A; Sasaki Y; Eguchi K; Tamura T; Ohe Y
    Cancer Chemother Pharmacol; 1994; 34 Suppl():S112-7. PubMed ID: 8070019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I clinical and pharmacologic study of a carboplatin and irinotecan regimen combined with recombinant human granulocyte-colony stimulating factor in the treatment of patients with advanced nonsmall cell lung carcinoma.
    Okamoto H; Nagatomo A; Kunitoh H; Kunikane H; Watanabe K
    Cancer; 1998 Jun; 82(11):2166-72. PubMed ID: 9610696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of irinotecan and etoposide in patients with metastatic non-small-cell lung cancer.
    Oshita F; Noda K; Nishiwaki Y; Fujita A; Kurita Y; Nakabayashi T; Tobise K; Abe S; Suzuki S; Hayashi I; Kawakami Y; Matsuda T; Tsuchiya S; Takahashi S; Tamura T; Saijo N
    J Clin Oncol; 1997 Jan; 15(1):304-9. PubMed ID: 8996157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ifosfamide, carboplatin, and etoposide plus granulocyte-macrophage colony-stimulating factor: a phase I study with apparent activity in non-small-cell lung cancer.
    Krigel RL; Palackdharry CS; Padavic K; Haas N; Kilpatrick D; Langer C; Comis R
    J Clin Oncol; 1994 Jun; 12(6):1251-8. PubMed ID: 8201386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer.
    Masuda N; Fukuoka M; Takada M; Kusunoki Y; Negoro S; Matsui K; Kudoh S; Takifuji N; Nakagawa K; Kishimoto S
    J Clin Oncol; 1992 Nov; 10(11):1775-80. PubMed ID: 1328551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study of sequentially administered topoisomerase I inhibitor (irinotecan) and topoisomerase II inhibitor (etoposide) for metastatic non-small-cell lung cancer.
    Ando M; Eguchi K; Shinkai T; Tamura T; Ohe Y; Yamamoto N; Kurata T; Kasai T; Ohmatsu H; Kubota K; Sekine I; Hojo N; Matsumoto T; Kodama T; Kakinuma R; Nishiwaki Y; Saijo N
    Br J Cancer; 1997; 76(11):1494-9. PubMed ID: 9400948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I/II study of cisplatin, ifosfamide and irinotecan with rhG-CSF support in patients with stage IIIB and IV non-small-cell lung cancer.
    Fujita A; Takabatake H; Tagaki S; Sekine K
    Cancer Chemother Pharmacol; 2000; 45(4):279-83. PubMed ID: 10755315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination docetaxel/cyclophosphamide in patients with advanced solid tumors.
    Valero V
    Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):34-6. PubMed ID: 9364540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non-small-cell lung cancer.
    Millward MJ; Zalcberg J; Bishop JF; Webster LK; Zimet A; Rischin D; Toner GC; Laird J; Cosolo W; Urch M; Bruno R; Loret C; James R; Blanc C
    J Clin Oncol; 1997 Feb; 15(2):750-8. PubMed ID: 9053501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer.
    Johnson FM; Kurie JM; Peeples BO; Lee JJ; Feng L; Pisters KM; Fossella FV; Papadimitrakopoulou VA; Blumenschein GR; Komaki R; Glisson BS
    Clin Lung Cancer; 2003 Jul; 5(1):40-5. PubMed ID: 14596703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors.
    Rowinsky EK; Grochow LB; Sartorius SE; Bowling MK; Kaufmann SH; Peereboom D; Donehower RC
    J Clin Oncol; 1996 Apr; 14(4):1224-35. PubMed ID: 8648378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignancies.
    Rowinsky EK; Rizzo J; Ochoa L; Takimoto CH; Forouzesh B; Schwartz G; Hammond LA; Patnaik A; Kwiatek J; Goetz A; Denis L; McGuire J; Tolcher AW
    J Clin Oncol; 2003 Jan; 21(1):148-57. PubMed ID: 12506184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.